Lu Jun, Shi Yewei, Lan Xin, Tang Guangling, Shao Yi, Chen Chao, Xiong Xinglong, Chen Dongxu, Shi Jing
Department of Anesthesiology, Affiliated Hospital of Guizhou Medical University, Guiyang, People's Republic of China.
Department of Anesthesiology, West China Second Hospital, Sichuan University, Chengdu, People's Republic of China.
Drug Des Devel Ther. 2025 Aug 29;19:7541-7552. doi: 10.2147/DDDT.S536225. eCollection 2025.
To investigate the effects of ciprofol on postoperative cognitive function in patients undergoing cardiac surgery with cardiopulmonary bypass (CPB).
A total of 138 patients who underwent cardiac surgery with cardiopulmonary bypass were included in this prospective, randomized, controlled study. Patients were randomized into two groups: the Ciprofol group (Group C) and the Propofol group (Group P). During anesthesia induction and maintenance, the patients in Group C received ciprofol, whereas those in Group P received propofol. The primary outcome measure was the incidence of postoperative delirium (POD), which was assessed twice daily for 7 days after surgery via either the Confusion Assessment Method (CAM) or the Confusion Assessment Method for the Intensive Care Unit (CAM-ICU). Statistical analyses included chi-square tests for categorical outcomes and relative risk calculations for POD. Additionally, delirium subtypes were recorded. The incidence of postoperative cognitive dysfunction (POCD) was evaluated at 1 and 3 months after surgery using the Telephone Montreal Cognitive Assessment (T-MoCA). Furthermore, the occurrence of postinduction adverse events, including hypotension, bradycardia, and tachycardia, as well as the incidence of postoperative complications, were also documented.
POD occurred in 19/64 (29.69%) patients in the Ciprofol group and 34/65 (52.31%) patients in the Propofol group (RR = 0.57; 95% confidence interval = 0.37 to 0.88; = 0.009). There was no significant difference in the incidence of POCD at 1 month (22.03% vs 26.62%, = 0.547) or 3 months (16.25% vs 16.00%; = 0.771) after surgery between the two groups.
Ciprofol was found to decrease the incidence of POD in patients who underwent cardiac surgery with cardiopulmonary bypass. Nevertheless, no significant effect of this intervention on the incidence of POCD was demonstrated at either 1 or 3 months after surgery. A reduction in the incidence of delirium may be associated with improved postoperative recovery, shortened hospital stays, and a decrease in long-term cognitive impairments.
The study had been registered in the Chinese Clinical Trials Registry (www.chictr.org.cn; Trial Identifier: ChiCTR2200061712).
探讨环泊酚对体外循环心脏手术患者术后认知功能的影响。
本前瞻性、随机、对照研究纳入了138例行体外循环心脏手术的患者。患者被随机分为两组:环泊酚组(C组)和丙泊酚组(P组)。在麻醉诱导和维持期间,C组患者接受环泊酚,而P组患者接受丙泊酚。主要观察指标是术后谵妄(POD)的发生率,术后7天每天通过意识模糊评估法(CAM)或重症监护病房意识模糊评估法(CAM-ICU)评估两次。统计分析包括分类结果的卡方检验和POD的相对风险计算。此外,记录谵妄亚型。术后1个月和3个月使用电话蒙特利尔认知评估(T-MoCA)评估术后认知功能障碍(POCD)的发生率。此外,还记录了诱导后不良事件的发生情况,包括低血压、心动过缓和心动过速,以及术后并发症的发生率。
环泊酚组19/64(29.69%)的患者发生POD,丙泊酚组34/65(52.31%)的患者发生POD(RR = 0.57;95%置信区间 = 0.37至0.88;P = 0.009)。两组术后1个月(22.03%对26.62%,P = 0.547)或3个月(16.25%对16.00%;P = 0.771)POCD的发生率无显著差异。
发现环泊酚可降低体外循环心脏手术患者POD的发生率。然而,在术后1个月或3个月,该干预措施对POCD的发生率均未显示出显著影响。谵妄发生率的降低可能与术后恢复改善、住院时间缩短以及长期认知障碍减少有关。
本研究已在中国临床试验注册中心(www.chictr.org.cn;试验注册号:ChiCTR2200061712)注册。